Illumina Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Illumina şirketinin kazançları yıllık ortalama -55.7% oranında azalırken, Life Sciences sektörünün kazançları yıllık 11.7% oranında artan oldu. Gelirler yıllık ortalama 6.7% oranında artan oldu.

Anahtar bilgiler

-55.7%

Kazanç büyüme oranı

-55.7%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	21.5%
Gelir büyüme oranı	6.7%
Özkaynak getirisi	-74.6%
Net Marj	-36.1%
Son Kazanç Güncellemesi	29 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Jul 01

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

May 26

Illumina: Expect A Slow Rebound

May 07

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Apr 26

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Mar 20

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Feb 23

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Jan 26

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Jan 19

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22

The Big Trends: New Frontiers in Healthcare

Jul 13

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14

Gelir ve Gider Dağılımı

Illumina nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:ILMN Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
29 Sep 24	4,390	-1,585	1,354	1,118
30 Jun 24	4,429	-3,044	1,365	1,179
31 Mar 24	4,493	-1,290	1,646	1,204
31 Dec 23	4,504	-1,161	1,637	1,207
01 Oct 23	4,465	-1,125	1,572	1,234
02 Jul 23	4,461	-4,186	1,705	1,246
02 Apr 23	4,448	-4,487	1,636	1,227
01 Jan 23	4,584	-4,404	1,614	1,209
02 Oct 22	4,700	-4,153	1,682	1,242
03 Jul 22	4,693	-20	1,510	1,187
03 Apr 22	4,656	701	1,550	1,061
02 Jan 22	4,526	762	1,744	914
03 Oct 21	4,280	907	1,351	794
04 Jul 21	3,966	769	1,350	696
04 Apr 21	3,473	630	1,114	650
03 Jan 21	3,239	656	1,014	609
27 Sep 20	3,238	638	813	572
28 Jun 20	3,351	693	811	551
29 Mar 20	3,556	942	835	562
29 Dec 19	3,543	1,002	907	575
29 Sep 19	3,458	973	874	607
30 Jun 19	3,405	938	881	615
31 Mar 19	3,397	851	877	600
30 Dec 18	3,333	826	849	568
30 Sep 18	3,243	684	798	538
01 Jul 18	3,103	648	768	513
01 Apr 18	2,936	567	732	492
31 Dec 17	2,752	725	720	500
01 Oct 17	2,594	775	692	488
02 Jul 17	2,487	741	664	480
02 Apr 17	2,424	730	652	474
01 Jan 17	2,398	454	630	458
02 Oct 16	2,371	440	624	450
03 Jul 16	2,314	430	621	423
03 Apr 16	2,253	415	597	395
03 Jan 16	2,220	462	561	362
27 Sep 15	2,141	510	533	348
28 Jun 15	2,071	486	516	334
29 Mar 15	1,979	430	506	321
28 Dec 14	1,861	353	499	306
28 Sep 14	1,736	281	478	294
29 Jun 14	1,612	219	453	279
30 Mar 14	1,511	208	430	264
29 Dec 13	1,421	125	423	249

Kaliteli Kazançlar: ILMN şu anda kârlı değil.

Büyüyen Kar Marjı: ILMN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ILMN kârlı değildir ve zararlar son 5 yılda yılda 55.7% oranında artmıştır.

Büyüme Hızlandırma: ILMN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ILMN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Life Sciences sektörüyle ( -4.7% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ILMN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -74.59% ) sahiptir.

Illumina Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Illumina, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Recent updates

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina: Q3 Confirms Improving Fundamentals

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina to Preview Newest Innovations in NGS and Multiomic Technologies At the American Society of Human Genetics Annual Meeting

We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Illumina, Inc. Introduces the MiSeq i100 Series

Illumina, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Consensus EPS estimates fall from profit to US$1.71 loss

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Consensus EPS estimates upgraded to US$0.93 loss

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Now 24% overvalued

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Now 22% overvalued

Illumina: Expect A Slow Rebound

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Consensus EPS estimates fall by 25%

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Consensus EPS estimates upgraded to US$0.56 loss

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

CEO & Director recently bought US$992k worth of stock

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Full year 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 20% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Price target decreased by 15% to US$168

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

Price target decreased by 9.4% to US$203

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Price target decreased by 7.0% to US$224

Second quarter 2023 earnings: EPS misses analyst expectations